2
Mar
2022

Rondo Raises $67M to Make Bispecific T-cell Engagers for Solid Tumors

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Bispecific Antibodies for Cancer: Shelley Force Aldred and Nathan Trinklein on The Long Run